Introduction {#s1}
============

130--170 million people worldwide are currently infected with hepatitis C virus (HCV) [@pcbi.1001072-Lavanchy1]. Over 70% of HCV infections become chronic and if untreated may lead to cirrhosis and hepatocellular carcinoma, necessitating liver transplantation [@pcbi.1001072-Lavanchy1]. The standard of care for HCV infection involves combination therapy with pegylated interferon and ribavirin [@pcbi.1001072-Ghany1]. Ribavirin alone does not elicit a lasting antiviral response [@pcbi.1001072-Dusheiko1]--[@pcbi.1001072-Pawlotsky1], yet it substantially improves treatment response in combination with interferon [@pcbi.1001072-Manns1]--[@pcbi.1001072-Poynard1]. For instance, whereas ∼29% of the patients treated with interferon exhibited a sustained virological response (SVR), the response rate increased to ∼56% upon addition of ribavirin [@pcbi.1001072-Fried1]. Ribavirin, however, is associated with the side-effect, hemolytic anemia, which often renders therapy intolerable [@pcbi.1001072-Bodenheimer1], [@pcbi.1001072-Franceschi1]--[@pcbi.1001072-Sulkowski2]. With the standard ribavirin dosage of 1000--1200 mg/day, 54% of the patients treated experienced a decline in the hemoglobin (Hb) level of over 3 g/dL, and 10% of the men and 7% of the women treated experienced an Hb decline of over 5 g/dL (normal Hb range: 14--16 g/dL) [@pcbi.1001072-Sulkowski2]. This drop in Hb often necessitates a reduction of ribavirin dosage, which significantly compromises treatment response [@pcbi.1001072-Manns1], [@pcbi.1001072-Sulkowski1], [@pcbi.1001072-Reddy1], [@pcbi.1001072-Reddy2]. The probability of achieving SVR is estimated to decrease from ∼65% to ∼45% when ribavirin dosage is reduced from ∼15 mg/kg to ∼7 mg/kg of body weight, in combination with pegylated interferon at 1.5 µg/kg of body weight [@pcbi.1001072-Manns1]. Patients receiving fewer than 60% of the planned ribavirin doses had lower response rates [@pcbi.1001072-Reddy1], indicating that lower cumulative ribavirin exposure results in poorer treatment response [@pcbi.1001072-Sulkowski1], [@pcbi.1001072-Reddy2]. The rates of relapse of infection following the end of treatment also increased upon lowering ribavirin dosage [@pcbi.1001072-Reddy1], [@pcbi.1001072-Reddy2]. In a recent clinical trial where interferon was employed with telaprevir, a promising new inhibitor of HCV protease, response rates were lowest in patients who were not administered ribavirin [@pcbi.1001072-Hazode1], underscoring the importance of ribavirin in achieving SVR.

Alternatives for patients who do not respond to combination therapy do not exist yet [@pcbi.1001072-Ghany1], [@pcbi.1001072-Lemon1]. Significant efforts are underway therefore to identify treatment protocols that maximize response rates to combination therapy while curtailing side-effects [@pcbi.1001072-Reddy2], [@pcbi.1001072-Zeuzem1]--[@pcbi.1001072-DebRoy1]. A particularly promising strategy is to supplement combination therapy with growth hormones, such as erythropoietin, that stimulate erythropoiesis and thus avert the reduction of ribavirin dosage, potentially improving treatment response [@pcbi.1001072-Dieterich1]--[@pcbi.1001072-Falasca1]. The predominant mechanism(s) of the anti-HCV activity of ribavirin remain to be established [@pcbi.1001072-Feld1]--[@pcbi.1001072-Dixit1]. Mathematical models of viral kinetics have been developed that describe the antiviral activity of interferon and the enhancement of treatment response rates due to ribavirin, and are being extended to predict the impact of new antiviral drugs [@pcbi.1001072-Dixit1]--[@pcbi.1001072-Rong2]. Ribavirin-induced anemia, on the other hand, remains poorly understood [@pcbi.1001072-Sulkowski1], [@pcbi.1001072-Tod1], [@pcbi.1001072-DebRoy1], [@pcbi.1001072-Vlierberghe1]--[@pcbi.1001072-Inoue1] and precludes rational optimization of combination therapy.

Here, we construct a mathematical model of the population dynamics of erythrocytes that quantitatively describes ribavirin-induced anemia and informs future strategies for improving outcomes of combination therapy. Model predictions capture experimental observations of the accumulation of ribavirin in erythrocytes and the ensuing Hb decline in HCV patients following the onset of combination therapy, estimate the enhanced turnover rate of erythrocytes during therapy and the threshold ribavirin exposure beyond which anemia is intolerable, present guidelines for the optimal usage of growth hormone supplements, and provide a framework, in conjunction with models of viral kinetics, for rational optimization of combination therapy.

Results {#s2}
=======

Model formulation {#s2a}
-----------------

Prior to the onset of treatment with ribavirin, the population of erythrocytes (RBCs) in an HCV infected individual is constant; a balance exists between RBC production and death ([Fig. 1](#pcbi-1001072-g001){ref-type="fig"}). Following the onset of treatment, ribavirin administered orally gets rapidly transported from the plasma to RBCs, where it is phosphorylated to its mono-, di- and tri-phosphate analogs (RMP, RDP, and RTP) [@pcbi.1001072-Glue1]. Phosphorylated analogs are neither easily metabolized nor transported out of RBCs [@pcbi.1001072-Glue1]. Consequently, ribavirin accumulates inside RBCs in the form of its phosphorylated analogs; the total intracellular concentration of ribavirin can be \>100-fold its extracellular concentration [@pcbi.1001072-Inoue1]. This dramatic accumulation of ribavirin may induce oxidative damage and result in enhanced extra vascular death of RBCs [@pcbi.1001072-Franceschi1]. Indeed, RBC lifespan decreased from 107±22 d in HCV patients not exposed to ribavirin to 39±13 d in HCV patients undergoing treatment with ribavirin [@pcbi.1001072-Krishnan1], [@pcbi.1001072-Virtue1]. The shortened RBC lifespan creates an imbalance between RBC production and death and results in a decline in the RBC population. Accordingly, Hb levels drop and patients become anemic. We construct a mathematical model to describe this dynamics of ribavirin-induced anemia ([Methods](#s4){ref-type="sec"}).

![Schematic of the population dynamics of RBCs in HCV infected individuals.\
**A**, Before the onset of combination therapy, the production and death rates of RBCs are balanced and the population of RBCs in plasma is constant. **B**, Following the onset of therapy, ribavirin enters RBCs and increases their death rates. Cells born at different times are exposed to ribavirin for different durations and hence carry different concentrations of ribavirin. The enhanced death rate lowers the RBC population, which triggers an increase in the RBC production from the bone marrow by a negative feedback through the hormone erythropoietin.](pcbi.1001072.g001){#pcbi-1001072-g001}

Model predictions {#s2b}
-----------------

### Population dynamics of RBCs during treatment with ribavirin {#s2b1}

We present model predictions in terms of the cumulative population, , which is the population of RBCs at time *t* following the onset of treatment in which the concentration of ribavirin phosphorylated analogs, RXP, is less than or equal to *C* ([Fig. 2A](#pcbi-1001072-g002){ref-type="fig"}). (RXP comprises RMP, RDP, and RTP.) At the start of treatment , no cells contain RXP, and for all *C*, where *N* ~0~ is the steady population of RBCs prior to the onset of treatment. In other words, the population of cells carrying RXP at concentrations smaller than or equal to *C* is *N* ~0~ for all . At , the production and death rates of RBCs are in balance ([Fig. 2B](#pcbi-1001072-g002){ref-type="fig"}), the hemoglobin level, *Hb* = *Hb* ~0~, and the average intracellular concentration of ribavirin, ([Fig. 2C](#pcbi-1001072-g002){ref-type="fig"}). With time, ribavirin accumulates inside cells. At any time , a distribution of RXP concentrations across cells emerges with cells exposed to ribavirin longer possessing higher concentrations of RXP. Thus, cells present from the start of treatment possess the highest concentration of RXP. At d, for instance, the latter cells possess RXP at the concentration , where *C* ~max~ =  is the maximum intracellular concentration of RXP for a given extracellular concentration of ribavirin ([Fig. 2A](#pcbi-1001072-g002){ref-type="fig"}). Cells born after the onset of treatment possess RXP at concentrations smaller than at d. Because most of the cells present at d are from the population that existed at the start of therapy, exhibits a sharp rise at and reaches the value *N*(*t* = 1) ([Fig. 2A](#pcbi-1001072-g002){ref-type="fig"}). With time, the sharp rise in shifts to higher values of ([Fig. 2A](#pcbi-1001072-g002){ref-type="fig"}) indicating greater accumulation of RXP. Accordingly, increases ([Fig. 2C](#pcbi-1001072-g002){ref-type="fig"}). Cells die at increasing rates as intracellular RXP accumulates ([Fig. 2B](#pcbi-1001072-g002){ref-type="fig"}). The population of RBCs, *N*(*t*), and, hence, correspondingly decrease ([Fig. 2C](#pcbi-1001072-g002){ref-type="fig"}). New cells are continuously produced at a rate that increases as the RBC population declines ([Fig. 2B](#pcbi-1001072-g002){ref-type="fig"}). Eventually, a new balance between RBC production and death is attained, reaches a steady distribution, reaches an asymptotic maximum , and attains a new, lower steady value .

![Model predictions of the dynamics of ribavirin-induced anemia.\
**A**, The cumulative population, *m*(*C*,*t*), of RBCs as a function of the intracellular concentration of RXP, *C*, at different times, *t*, following the onset of combination therapy, predicted by Eqs. (1)--(3). Parameters employed are listed in [Table 1](#pcbi-1001072-t001){ref-type="table"}. *m*(*C*,*t*) is normalized by *N* ~0~ and *C* by *C* ~max~ = . **B**, The production rate, *P*(*t*), and the death rate of RBCs. **C**, The corresponding change in *Hb* (red) and *C* ~avg~ (green).](pcbi.1001072.g002){#pcbi-1001072-g002}

### Factors that influence the severity of ribavirin-induced anemia {#s2b2}

An increase in the steady state plasma concentration of ribavirin, , which may be achieved with a higher dosage, results in an increase in and a decrease in , illustrating the more severe anemia that results with increased ribavirin exposure. For instance, increasing from 5 µM to 15 µM increases the total drop in *Hb*, , from ∼2 g/dL to ∼5 g/dL ([Fig. 3A](#pcbi-1001072-g003){ref-type="fig"}). An increase in the intracellular phosphorylation rate, , (or a decrease in the loss rate of intracellular RXP, ) results in a higher for the same , which in turn elevates cell death rates and lowers . Thus, increases from ∼2.5 g/dL when d^−1^ to ∼3.5 g/dL when d^−1^ ([Fig. 3B](#pcbi-1001072-g003){ref-type="fig"}), illustrating that differences in the intracellular metabolism of ribavirin may contribute to inter-patient variations in the severity of ribavirin-induced anemia. Enhancing the RBC production rate, by increasing (see Eq. (3)), (or lowering the sensitivity of the RBC death rate to ribavirin accumulation, by increasing or decreasing (see Eq. (2))), reduces ([Fig. 3C](#pcbi-1001072-g003){ref-type="fig"}). Administration of growth hormones, such as erythropoietin, enhances the RBC production rate, which reduces for the same ribavirin exposure and thus improves the tolerability of ribavirin. Similarly, decrease in the intracellular inosine triphosphatase level, observed recently in some patients [@pcbi.1001072-Fellay1], may interfere with RTP activity and lower the sensitivity of the RBC death rate to ribavirin, which also reduces and improves the tolerability of ribavirin.

![Factors influencing the dynamics of ribavirin-induced anemia.\
Changes in *Hb* (red) and *C* ~avg~ (green) predicted by Eqs. (1)--(3) for different parameter values: **A**, 5 µM (solid lines), 10 µM (dashed lines) and 15 µM (dotted lines). **B**, (solid lines), 65 d^−1^ (dashed lines), 80 d^−1^ (dotted lines). **C**, (solid lines), (dashed lines), (dotted lines). The other parameters are mentioned in [Table 1](#pcbi-1001072-t001){ref-type="table"}.](pcbi.1001072.g003){#pcbi-1001072-g003}

### Inter-patient variations {#s2b3}

Inter-patient variability in the severity of anemia may arise from variations in the intracellular uptake, accumulation, or metabolism of ribavirin, as well as in the dependence of the RBC lifespan on ribavirin accumulation and in the sensitivity of the RBC production rate to changes in *Hb*. To obtain a measure of this inter-patient variability, we calculated using 500 different combinations of the values of the parameters, , , and , for a range of values of . The parameter values for each combination were chosen randomly from Gaussian distributions based on the mean values and confidence levels of the respective parameters obtained from comparisons of our model predictions with patient data (see below). Indeed, we find that inter-patient variations in may be substantial for any ribavirin exposure ([Fig. 4A](#pcbi-1001072-g004){ref-type="fig"}) or intracellular accumulation ([Fig. 4B](#pcbi-1001072-g004){ref-type="fig"}). Further, the variation increases with increase in ribavirin exposure and intracellular accumulation.

![Model predictions of the variations in the severity of ribavirin-induced anemia.\
The reduction in *Hb* () predicted by Eqs. (1)--(3) as a function of **A**, , and **B**, , for 500 different combinations of the parameter values (mean±s.d.) , , , , and . The standard deviations on the parameter values correspond to the 95% confidence limits obtained from the best-fits to patient data (see [Fig. 5](#pcbi-1001072-g005){ref-type="fig"}). The other parameters are mentioned in [Table 1](#pcbi-1001072-t001){ref-type="table"}.](pcbi.1001072.g004){#pcbi-1001072-g004}

Below, we compare our model predictions with experiments.

Comparisons of model predictions with patient data {#s2c}
--------------------------------------------------

We consider a recent study of the time-evolution of and in 19 Japanese patients following the onset of combination therapy [@pcbi.1001072-Inoue1]. In this latter study, no reduction of ribavirin dosage is reported. The patients were divided into two groups based on whether \<1000 µM (7 patients) or \>1000 µM (12 patients); the data are reported as the average within each group. We fit model predictions of and to the data of the former 7 patients using , , and as adjustable parameters. (Interferon may also induce anemia, but does so to a much smaller extent than ribavirin [@pcbi.1001072-Sulkowski1]. We therefore assume that the *Hb* decline in patients undergoing combination therapy is primarily due to ribavirin.) We fix the remaining parameters based on previous studies or from analysis of independent experiments ([Methods](#s4){ref-type="sec"}). Model predictions provide good fits to the data and yield estimates of , , and ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"}). The fits suggest that our model is able to describe the underlying dynamics of ribavirin-induced anemia in HCV patients.

![Comparisons of model predictions with experiments.\
**A**, Best-fits of model predictions (lines) of *Hb* (red) and *C* ~avg~ (green) with experimental data (symbols) from 7 Japanese patients with \<1000 µM [@pcbi.1001072-Inoue1]. We let *Hb* ~0~ = 14.4 g/dL and following the mean reported values for these patients [@pcbi.1001072-Inoue1]. We use , , , and as adjustable parameters. The remaining parameters are mentioned in [Table 1](#pcbi-1001072-t001){ref-type="table"}. The resulting best-fit parameter estimates (95% CI) are , , , and . Dashed lines show 95% confidence intervals on the predictions. **B**, Comparisons of our predictions (lines) of *Hb* (red) and *C* ~avg~ (green) using the parameters above with data (symbols) from 12 Japanese patients with \>1000 µM (solid circles) [@pcbi.1001072-Inoue1]. In the latter patients, the mean *Hb* ~0~≈15 g/dL and . We also show comparisons with independent data from 20 patients [@pcbi.1001072-Homoncik1] (open circles) with mean *Hb* ~0~ = 15.1 g/dL. Solid lines are predictions with *Hb* ~0~ = 15.1 g/dL and , and the mean parameters mentioned above, and dashed lines represent standard deviations. **C**, **D**, Model predictions (lines) and experimental observations (symbols) of the reduction in *Hb* () under combination therapy as a function of **C**, , and **D**, , in 19 Japanese patients [@pcbi.1001072-Inoue1]. Solid lines represent predictions with the mean parameter values above and dashed lines represent standard deviations obtained from several hundred realizations of our model predictions for different combinations of the values of , , , and generated randomly from distributions based on the best-fit parameter estimates and 95% confidence limits mentioned above.](pcbi.1001072.g005){#pcbi-1001072-g005}

Interestingly, with the same parameter values, our model captures changes in *Hb* and from the other 12 Japanese patients, as well as an independent data set of *Hb* decline in another group of HCV patients undergoing combination therapy [@pcbi.1001072-Homoncik1] ([Fig. 5B](#pcbi-1001072-g005){ref-type="fig"}), validating our best-fit parameter estimates. Further, with the same parameter values, we estimate that the RBC lifespan is 38 days (95% CI: 19--55 days) in Japanese patients with \<1000 µM and 33 days (95% CI: 14--53 days) in Japanese patients with \>1000 µM. These estimates of the RBC lifespan are in close agreement with independent estimates, 39±13 days, from measurements of alveolar carbon monoxide [@pcbi.1001072-Krishnan1], [@pcbi.1001072-Virtue1], presenting another successful test of our model. Finally, we find that our predictions of the dependence of on and using the same parameters above are also in agreement with observations in the Japanese patients [@pcbi.1001072-Inoue1] ([Fig. 5C,D](#pcbi-1001072-g005){ref-type="fig"}). Our model thus presents a robust description of ribavirin-induced anemia in HCV patients undergoing combination therapy.

Clinical implications {#s2d}
---------------------

Our model has several clinical implications. First, it enables estimation of the threshold ribavirin exposure beyond which anemia is intolerable. Current treatment guidelines recommend a reduction of ribavirin dosage when *Hb* decreases below 10 g/dL. We apply our model to predict as a function of . We find that on average (when  = 14.4 g/dL) \<10 g/dL when \>13 µM ([Fig. 6A](#pcbi-1001072-g006){ref-type="fig"}). Thus, steady state plasma concentrations above 13 µM would render ribavirin therapy intolerable. While the dependence of the peak plasma concentration on dosage following a single ribavirin dose has been determined [@pcbi.1001072-Glue1], the dependence of on dosage remains to be established. A description of the multiple dose pharmacokinetics of ribavirin, which also remains elusive [@pcbi.1001072-Pawlotsky1], [@pcbi.1001072-Dixit1], [@pcbi.1001072-Glue1], [@pcbi.1001072-Preston1], [@pcbi.1001072-Endres1], would establish the dosage corresponding to of 13 µM that would render ribavirin intolerable.

![Model predictions of threshold ribavirin exposure and requisite RBC production.\
**A**, Prediction of as a function of . The arrow indicates the threshold above which \<10 g/dL. **B**, Predictions of the RBC production rate during therapy (black) and the production rate required to maintain of 10 g/dL (pink) and 12 g/dL (blue) as functions of . The arrows indicate the desired production rates when . Parameter values employed are mentioned in [Table 1](#pcbi-1001072-t001){ref-type="table"}.](pcbi.1001072.g006){#pcbi-1001072-g006}

Second, when is above the threshold, our model allows estimation of the increase in RBC production, which may be achieved by administration of exogenous growth hormones such as recombinant erythropoietin, necessary to avert the currently recommended reduction of dosage. Because growth hormones also have side-effects [@pcbi.1001072-Homoncik1], [@pcbi.1001072-McHutchison2], one strategy is to use them at levels just enough to increase to 10--12 g/dL (rather than the pretreatment level), which renders ribavirin tolerable [@pcbi.1001072-Reddy2]. We apply our model to predict the level of RBC production necessary for achieving of 10--12 g/dL for different values of ([Fig. 6B](#pcbi-1001072-g006){ref-type="fig"}). Thus, when  = 15 µM, RBC production rates of 8.44 and 10.2 million cells s^−1^ are necessary for ensuring of 10 and 12 g/dL, respectively. Increase in endogenous erythropoietin levels during therapy, also observed experimentally [@pcbi.1001072-Balan1], [@pcbi.1001072-Mangoni1], results in an enhanced production rate of 8.1 million cells s^−1^, which is 3.5-fold higher than the basal production rate (here 2.3 million cells s^−1^ in the absence of ribavirin) but inadequate to achieve the desired . Hormone supplements may be employed to provide the balance of 0.34 or 2.1 million cells s^−1^ increase in the RBC production rate to ensure of 10 or 12 g/dL, respectively. This deficiency in RBC production that hormone supplements must compensate increases with ribavirin exposure ([Fig. 6B](#pcbi-1001072-g006){ref-type="fig"}).

Discussion {#s3}
==========

The ability to enhance treatment response rates renders ribavirin central to the treatment of HCV infection. Maximizing the benefit of ribavirin to patients requires striking the right balance between its antiviral activity and its treatment-limiting side-effect, hemolytic anemia. Rational approaches to therapy optimization thus rely on quantitative descriptions of both the antiviral and the hemolytic activities of ribavirin. Extant mathematical models predict the enhancement in treatment response due to ribavirin [@pcbi.1001072-Dixit1]--[@pcbi.1001072-Rong2]. Ribavirin-induced anemia, however, remains poorly described and limits our ability to maximize treatment response. Here, we fill this gap by constructing a model of the population dynamics of RBCs that quantitatively describes ribavirin-induced anemia. By assuming that intracellular accumulation of ribavirin enhances RBC death rate in a dose-dependent manner, our model captures several independent observations of ribavirin-induced anemia in HCV patients undergoing combination therapy. In particular, our model predicts the dynamics of the accumulation of ribavirin in RBCs and the resulting decline of *Hb* in patients following the onset of therapy, estimates the reduced lifespan of RBCs during therapy, and describes inter-patient variations in the severity of anemia, thus presenting a robust description of ribavirin-induced anemia, which, in conjunction with models of viral kinetics, may facilitate identification of treatment protocols that maximize the impact of ribavirin in the treatment of HCV infection.

Our model has clinical implications. First, it allows estimation of the threshold ribavirin exposure beyond which ribavirin-induced anemia becomes intolerable. For instance, with model parameters that describe ribavirin-induced anemia in the patients we considered ([Fig. 5](#pcbi-1001072-g005){ref-type="fig"}), we estimate that steady state plasma ribavirin concentrations above 13 µM would render ribavirin therapy intolerable. Determining dosage levels corresponding to this steady state plasma concentration requires knowledge of the pharmacokinetics of ribavirin, which is currently lacking [@pcbi.1001072-Pawlotsky1], [@pcbi.1001072-Dixit1], [@pcbi.1001072-Glue1], [@pcbi.1001072-Preston1], [@pcbi.1001072-Endres1]. Ribavirin pharmacokinetics is peculiar because of an unusually long elimination phase that follows rapid absorption and distribution phases upon oral dosing [@pcbi.1001072-Glue1]. Standard absorption-elimination models of drug pharmacokinetics are unable to describe this long elimination phase. Models that include additional compartments have been proposed to capture the three-phase pharmacokinetics of ribavirin [@pcbi.1001072-Preston1], but the biological origin of these compartments remains unclear. An additional complication is that the half-life of the elimination phase increases from 79 h following a single dose to 274--298 h following multiple dosing [@pcbi.1001072-Glue1], suggesting that parameters that describe single dose pharmacokinetics may not apply to multiple dose pharmacokinetics. In the absence of rigorous models of ribavirin pharmacokinetics, one may have to rely on empirical relationships between the dosage and the resulting steady state plasma concentration following multiple dosing (e.g., [@pcbi.1001072-Glue2]) to establish the dosage that would ensure tolerability of ribavirin while maximizing treatment response.

Second, our model suggests guidelines for the usage of hormone supplements, such as erythropoietin, which enhance RBC production and improve the tolerability of ribavirin. For instance, we predict that when ribavirin accumulates to a plasma concentration of 15 µM, the associated enhanced RBC death rate elicits a natural response that increases RBC production 3.5-fold, from 2.3 to 8.1 million cells s^−1^. This response, however, is inadequate to suppress ribavirin-induced anemia adequately and renders ribavirin intolerable. We estimate then that growth hormone supplements must increase RBC production rate by an additional 0.34--2.1 million cells s^−1^ to render ribavirin tolerable. This compensation that hormone supplements must provide increases with ribavirin accumulation. Identifying the dosage of the growth hormones that induces the necessary RBC production requires knowledge of the dose-response relationships and of the pharmacokinetics of the growth hormones, which are yet to be fully elucidated [@pcbi.1001072-Dieterich1]--[@pcbi.1001072-Falasca1].

Third, genetic variations that resulted in a deficiency in the enzyme inosine triphosphatase (ITPA) were recently found to protect HCV patients against ribavirin-induced anemia [@pcbi.1001072-Fellay1]. Deficiency in ITPA causes an increase in inosine triphosphate levels in RBCs, which is thought to interfere with RTP activity and thereby suppress the hemolytic potential of ribavirin. Because deficiency in ITPA is a clinically benign condition, therapeutic intervention to suppress ITPA presents a promising new strategy to curtail ribavirin-induced anemia without compromising the antiviral activity of ribavirin [@pcbi.1001072-Fellay1]. Our model may be adapted to inform the development of such an intervention strategy. In our model, the dependence of the death rate of RBCs on ribavirin accumulation, determined by Eq. (2) ([Methods](#s4){ref-type="sec"}), would now be a function of the ITPA level. Thus, experiments that determine how variations in the ITPA level both in the absence and in the presence of ribavirin influence RBC lifespan would provide the necessary inputs for our model to account explicitly for the role of ITPA in ribavirin-induced anemia. The resulting model would enable determination of the minimal inhibition of ITPA necessary to maintain ribavirin-induced anemia within tolerable limits. Conversely, using information of the ITPA level intrinsic to a patient, the model can be applied to predict the maximum ribavirin dosage that the patient can tolerate, thus presenting an avenue for personalizing the treatment of HCV infection.

Methods {#s4}
=======

Model development {#s4a}
-----------------

We consider the RBC population in an individual at time *t* following the onset of treatment with ribavirin (*t* = 0) ([Fig. 1](#pcbi-1001072-g001){ref-type="fig"}). RBCs produced at different times in the interval from 0 to *t* will have been exposed to ribavirin for different durations and accordingly have different intracellular levels of ribavirin. We define as the population of RBCs that contain ribavirin phosphorylated analogs, RXP, which comprises RMP, RDP, and RTP, at concentrations between and at time . is thus the number density of RBCs containing RXP at concentration *C* at time *t*. The time evolution of is governed by the following equation ([Text S1](#pcbi.1001072.s005){ref-type="supplementary-material"})

The first term on the right-hand-side in Eq. (1) represents the change in due to intracellular phosphorylation of ribavirin. is the net rate of increase of *C* due to phosphorylation, is the intracellular concentration of (unphosphorylated) ribavirin, is the phosphorylation rate and is the rate of loss, including by possible slow dephosphorylation, of RXP. In vitro studies of ribavirin uptake by RBCs observe rapid (\<10 min) equilibration of intracellular and extracellular ribavirin [@pcbi.1001072-Endres1], [@pcbi.1001072-Jarvis1]. We assume therefore that , the concentration of ribavirin in plasma. With twice daily oral administration of ribavirin, rises from zero at and reaches an asymptotic maximum, , so that , where is the characteristic timescale of the accumulation of ribavirin in plasma [@pcbi.1001072-Pawlotsky1], [@pcbi.1001072-Dixit2].

The second term on the right-hand side of Eq. (1) accounts for the loss of RBCs due to their death. We assume that the death rate, *D*, of RBCs increases with as followswhere is the death rate of RBCs in the absence of ribavirin, is that value of at which the death rate doubles (or the lifespan halves) compared to that in the absence of ribavirin, and , analogous to the Hill coefficient, determines the sensitivity of to changes in . (A saturable form for *D*(*C*) appears inconsistent with available data; see [Text S2](#pcbi.1001072.s006){ref-type="supplementary-material"}, [Fig. S1](#pcbi.1001072.s001){ref-type="supplementary-material"}.)

Equation (1) is constrained by the initial condition that in all cells at the start of therapy, so that , where *N* ~0~ is the population of RBCs at *t* = 0, and is the Dirac delta function, which satisfies and . In other words, the Dirac delta function ensures that no cells have RXP at non-zero concentrations at *t* = 0. A second constraint on Eq. (1) is imposed by the boundary condition that when \>0, newborn cells contain no RXP so that ([Text S1](#pcbi.1001072.s005){ref-type="supplementary-material"}) whereis the rate of production of RBCs at time *t*.

The production of RBCs by the bone marrow is regulated by a negative feedback mechanism involving the hormone erythropoietin [@pcbi.1001072-Spivak1]. Recent studies on modeling erythropoiesis elucidate the complexities involved in a quantitative description of this feedback mechanism [@pcbi.1001072-Mahaffy1]--[@pcbi.1001072-Savill1]. Here, we employ Eq. (3) to capture the essential features of this negative feedback: As the population of RBCs, , decreases, *P* increases. is the maximum production rate of RBCs, which occurs when *N* is vanishingly small, is that value of the RBC population per unit volume of blood () at which , is the volume of blood, and , analogous to the Hill coefficient, determines the sensitivity of to changes in . Eq. (3) provides good fits to independent measurements of the dynamics of the recovery of RBCs following phlebotomy ([Text S3](#pcbi.1001072.s007){ref-type="supplementary-material"}, [Fig. S2](#pcbi.1001072.s002){ref-type="supplementary-material"}).

Equations (1)--(3) present a model of the population dynamics of RBCs in individuals undergoing treatment with ribavirin. We solve the equations (see below) and obtain the population density, , and the corresponding cumulative population, , using which we predict the time-evolution of the hemoglobin level in blood, (where is the volume of a single erythrocyte); the average concentration of ribavirin in RBCs, ; and the average RBC lifespan, , where is the average death rate of RBCs.

Solution of model equations using the method of characteristics {#s4b}
---------------------------------------------------------------

Equation (1) along with the initial and boundary conditions is equivalent to the following set of differential equations obtained using the method of characteristics ([Text S4](#pcbi.1001072.s008){ref-type="supplementary-material"})where *S~i~*(*t*) is the subpopulation of cells born within an interval of that survive at time *t*. *C~i~*(*t*) is the concentration of RXP in the latter cells at time *t*. We solve Eq. (4) along with Eqs. (2) and (3) with d using a program written in MATLAB ([Text S5](#pcbi.1001072.s009){ref-type="supplementary-material"}). We validate our solution methodology against an analytical solution that can be obtained in the limiting case when the RBC death rate is independent of RXP accumulation ([Text S6](#pcbi.1001072.s010){ref-type="supplementary-material"}, [Fig. S3](#pcbi.1001072.s003){ref-type="supplementary-material"}). We also ensure that d allows accurate integration of Eq. (4) without compromising computational efficiency ([Fig. S4](#pcbi.1001072.s004){ref-type="supplementary-material"}). From the solution, we calculate the quantities of interest, viz., , , , and .

Model parameters {#s4c}
----------------

We employ the following values of the model parameters unless stated otherwise. The average RBC lifespan in normal man is ∼120 days [@pcbi.1001072-Krishnan1], [@pcbi.1001072-Berk1], which corresponds to d^−1^. We let *b* = 7 following earlier studies [@pcbi.1001072-Mahaffy1] and obtain cells d^−1^ from an independent analysis of blood loss experiments ([Text S3](#pcbi.1001072.s007){ref-type="supplementary-material"}). We fix and [@pcbi.1001072-Beck1]. Using [@pcbi.1001072-Inoue1], we get . We obtain from the initial steady state . Further, we let [@pcbi.1001072-Inoue1] and because ribavirin accumulates in plasma to its maximum concentration in ∼4 weeks, we set [@pcbi.1001072-Pawlotsky1], [@pcbi.1001072-Dixit2]. The remaining parameter values , , , and are obtained from best-fits of our model predictions to experimental data ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"}). We summarize model parameters and their values in [Table 1](#pcbi-1001072-t001){ref-type="table"}.

10.1371/journal.pcbi.1001072.t001

###### Summary of model parameters and their values employed.

![](pcbi.1001072.t001){#pcbi-1001072-t001-1}

  Parameter                                                         Description                                                        Value (95% CI)[a](#nt101){ref-type="table-fn"}                                     Source
  ----------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ -----------------------------------------------------------------------------
  *V*                                                             Volume of blood                                                                           5 L                                                    [@pcbi.1001072-Beck1]
  *v~e~*                                                         Volume of one RBC                                                                      9×10^−14^ L                                                [@pcbi.1001072-Beck1]
  *t~a~*                                     Characteristic timescale of accumulation of RBV in plasma                                                     5.4 d                                    [@pcbi.1001072-Pawlotsky1], [@pcbi.1001072-Dixit2]
  *b*                   Coefficient determining sensitivity of RBC production rate to changes in number per volume of RBCs                                   7                                                   [@pcbi.1001072-Mahaffy1]
  *D* ~0~                                         Death rate of RBCs in the absence of ribavirin                                                      8.3×10^−3^ d^−1^                               [@pcbi.1001072-Krishnan1], [@pcbi.1001072-Berk1]
  *Hb* ~0~                                                       Initial Hb level                                                                        14.4 g/dL                                                [@pcbi.1001072-Inoue1]
                                                       Steady state plasma RBV concentration                                                               7.5 µM                                                 [@pcbi.1001072-Inoue1]
                                    RBC population per unit volume at which RBC production rate is half maximal                                                                                         Determined from pretreatment steady state,
  *P~max~*                                                Maximum production rate of RBCs                                                          8.4×10^12^ cells d^−1^               Best-fit ([Text S3](#pcbi.1001072.s007){ref-type="supplementary-material"})
  *k~p~*                                             Phosphorylation rate of ribavirin in RBCs                                                       65 (47--84) d^−1^                           Best-fit ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"})
  *k~d~*                                       Loss rate of ribavirin phosphorylated analogs in RBCs                                                0.5 (0.3--0.7) d^−1^                         Best-fit ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"})
  *C* ~50~           Concentration of ribavirin phosphorylated analogs at which RBC death rate is twice the pretreatment value                       408 (189--628) µM                           Best-fit ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"})
  *γ*          Coefficient determining sensitivity of RBC death rate to changes in concentration of ribavirin phosphorylated analogs                    1 (0.2--1.8)                             Best-fit ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"})

Typical values employed. Variations are indicated in the text and in figure legends.

Fits of model predictions to patient data {#s4d}
-----------------------------------------

We fit model predictions to experimental data ([Fig. 5A](#pcbi-1001072-g005){ref-type="fig"}) using the nonlinear regression tool NLINFIT in MATLAB.
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